RESEARCH FINDINGS - CHOLESTEROL-LOWERING EFFECT
In 1981, Kaijivyama G et al reported the cholesterol-lowering effect of pantethine
using cholesterol diet rats. [Hiroshima J Med Sci. 1981 Sep;30(3):215-20]
In 1984, when Carrara et al were reporting the encouraging result on the cholesterol-
lowering effect of pantetine on experimental hypercholesterolemic rabbits
[Atherosclerosis. 1984 Dec; 53 (3):255-64], Arsenio L. et al reported the efficacy of
pantethine on the treatment of hyperlipidemia, diabetes and atherosclerosis in their
clinical study involving 37 hypercholesterolemic and/or hypertriglyceridemic patients.
[Acta Biomed Ateneo Parmense. 1984;55(1):25-42] In the same year, Gaddi A et al
also demonstrated the pantethine's cholesterol-lowering effect on 11 patients with
type IIB hyperlipoproteinemia, 15 patients with with type IV, and 3 patients with with
an isolated reduction of high density lipoprotein cholesterol (HDL-C) levels
[Atherosclerosis. 1984 Jan;50 (1):73-83]. Two years later, Bertolini S et al
demonstrated the therapeutic effectiveness of pantethine on hyperlipoproteinemic
pediatric patients. [Int J Clin Pharmacol Ther Toxicol. While, Binaghi P et al, Istitut
Clinici di Perfezionamento, Milano, Italy, demonstrated that pantethine was also
effective on lowering cholesterol in women aged 45-55. [Minerva Med. 1990 Jun;81(6):
475-9]
n the same period of time, Cighetti G et al, University of Milan, Italy, reported that
pantethine exerted its cholesterol-lowering effect actually by modulating the HMG-CoA
reductase activity (i.e. cholesterol synthesis). [Atherosclerosis. 1986 Apr;60 (1):67-77,
Biochim Biophys Acta. 1988 Nov 25;963(2):389-93].
In 1987, Arsenio L et al, Ospedali Riuniti, Parma, Italy, discovered that pantethine
could also exert its cholesterol-lowering effect via injection route. [Acta Biomed Ateneo
Parmense. 1987;58(5-6):143-52]
In 1987, Eto M. et al, Asahikawa Medical College, Japan, showed the lowering effect of
pantethine on plasma beta-thromboglobulin and lipids in diabetes mellitus from their
clinical trials. [Artery. 1987;15(1):1-12] Later on, Donati C. et al concluded that
pantethine should be considered for the treatment of lipid abnormalities also in
patients at risk such as those with diabetes mellitus in their review paper. [Clin Ter.
1989 Mar 31;128(6):411-22] Two years later, Coronel F et al, Hospital Universitario
San Carlos, Madrid, Spain, confirmed Donati C.Â’s suggestion from their clinical
studies. [Am J Nephrol. 1991;11(1):32-6]
Beside the possible application in diabetes mellitus, Osono Y et al, Aoyama Gakuin
University, Tokyo, Japan, found that oral administration of 600 mg.day of pantethine
could improve the conditions of fatty liver. [J Atheroscler Thromb. 2000;7(1):55-8].
RESEARCH FINDINGS
There are also reports that pantethine may protect liver and inhibit cataract: It may
also be an anti-oxidant.
Liver Protection
As early as 1957, Piccinellio O et al studied lipotropic & liver protective effect of
pantethine in experimental liver diseases induced by Handler diet & carbon
tetrachloride. [Farmaco [Prat]. 1957 Oct;12(10):799-822]. 13 years later, Sakamoto et
al, studied the influence of pantethine (PTSS), a derivative of pantothenic acid on
experimentally injured liver in rabbits [Zasshi Tokyo Ika Daigaku. 1970 Jul;28(4):597-
615] Consequently, Nagiel-Ostaszewski et al, St. John's University, Jamaica, NY,
reported protection by pantethine, pantothenic acid and cystamine against carbon
tetrachloride-induced hepatotoxicity in the rat [Res Commun Chem Pathol Pharmacol.
1990 Feb;67(2):289-92]
Lens Opacification
Clark JI et al, University of Washington, Seattle, reported delay or inhibition of rat lens
opacification using pantethine [Exp Eye Res. 1996 Jan;62(1):75-84]. While, Hiraoka T
et al, University of Washington School of Medicine, Seattle reported Inhibition of lens
opacification during the early stages of cataract formation [Invest Ophthalmol Vis Sci.
1995 Nov;36(12):2550-5].
Anti-Oxidant Activities
Slyshenkov VS et al, Nencki Institute of Experimental Biology, Warsaw, Poland,
reported that pantothenic acid and its related compounds protected the plasma
membrane of Ehrlich ascites tumor cells against the damage by oxygen free radicals.
[Free Radic Biol Med 1996;20(3):493]
In 1981, Kaijivyama G et al reported the cholesterol-lowering effect of pantethine
using cholesterol diet rats. [Hiroshima J Med Sci. 1981 Sep;30(3):215-20]
In 1984, when Carrara et al were reporting the encouraging result on the cholesterol-
lowering effect of pantetine on experimental hypercholesterolemic rabbits
[Atherosclerosis. 1984 Dec; 53 (3):255-64], Arsenio L. et al reported the efficacy of
pantethine on the treatment of hyperlipidemia, diabetes and atherosclerosis in their
clinical study involving 37 hypercholesterolemic and/or hypertriglyceridemic patients.
[Acta Biomed Ateneo Parmense. 1984;55(1):25-42] In the same year, Gaddi A et al
also demonstrated the pantethine's cholesterol-lowering effect on 11 patients with
type IIB hyperlipoproteinemia, 15 patients with with type IV, and 3 patients with with
an isolated reduction of high density lipoprotein cholesterol (HDL-C) levels
[Atherosclerosis. 1984 Jan;50 (1):73-83]. Two years later, Bertolini S et al
demonstrated the therapeutic effectiveness of pantethine on hyperlipoproteinemic
pediatric patients. [Int J Clin Pharmacol Ther Toxicol. While, Binaghi P et al, Istitut
Clinici di Perfezionamento, Milano, Italy, demonstrated that pantethine was also
effective on lowering cholesterol in women aged 45-55. [Minerva Med. 1990 Jun;81(6):
475-9]
n the same period of time, Cighetti G et al, University of Milan, Italy, reported that
pantethine exerted its cholesterol-lowering effect actually by modulating the HMG-CoA
reductase activity (i.e. cholesterol synthesis). [Atherosclerosis. 1986 Apr;60 (1):67-77,
Biochim Biophys Acta. 1988 Nov 25;963(2):389-93].
In 1987, Arsenio L et al, Ospedali Riuniti, Parma, Italy, discovered that pantethine
could also exert its cholesterol-lowering effect via injection route. [Acta Biomed Ateneo
Parmense. 1987;58(5-6):143-52]
In 1987, Eto M. et al, Asahikawa Medical College, Japan, showed the lowering effect of
pantethine on plasma beta-thromboglobulin and lipids in diabetes mellitus from their
clinical trials. [Artery. 1987;15(1):1-12] Later on, Donati C. et al concluded that
pantethine should be considered for the treatment of lipid abnormalities also in
patients at risk such as those with diabetes mellitus in their review paper. [Clin Ter.
1989 Mar 31;128(6):411-22] Two years later, Coronel F et al, Hospital Universitario
San Carlos, Madrid, Spain, confirmed Donati C.Â’s suggestion from their clinical
studies. [Am J Nephrol. 1991;11(1):32-6]
Beside the possible application in diabetes mellitus, Osono Y et al, Aoyama Gakuin
University, Tokyo, Japan, found that oral administration of 600 mg.day of pantethine
could improve the conditions of fatty liver. [J Atheroscler Thromb. 2000;7(1):55-8].
RESEARCH FINDINGS
There are also reports that pantethine may protect liver and inhibit cataract: It may
also be an anti-oxidant.
Liver Protection
As early as 1957, Piccinellio O et al studied lipotropic & liver protective effect of
pantethine in experimental liver diseases induced by Handler diet & carbon
tetrachloride. [Farmaco [Prat]. 1957 Oct;12(10):799-822]. 13 years later, Sakamoto et
al, studied the influence of pantethine (PTSS), a derivative of pantothenic acid on
experimentally injured liver in rabbits [Zasshi Tokyo Ika Daigaku. 1970 Jul;28(4):597-
615] Consequently, Nagiel-Ostaszewski et al, St. John's University, Jamaica, NY,
reported protection by pantethine, pantothenic acid and cystamine against carbon
tetrachloride-induced hepatotoxicity in the rat [Res Commun Chem Pathol Pharmacol.
1990 Feb;67(2):289-92]
Lens Opacification
Clark JI et al, University of Washington, Seattle, reported delay or inhibition of rat lens
opacification using pantethine [Exp Eye Res. 1996 Jan;62(1):75-84]. While, Hiraoka T
et al, University of Washington School of Medicine, Seattle reported Inhibition of lens
opacification during the early stages of cataract formation [Invest Ophthalmol Vis Sci.
1995 Nov;36(12):2550-5].
Anti-Oxidant Activities
Slyshenkov VS et al, Nencki Institute of Experimental Biology, Warsaw, Poland,
reported that pantothenic acid and its related compounds protected the plasma
membrane of Ehrlich ascites tumor cells against the damage by oxygen free radicals.
[Free Radic Biol Med 1996;20(3):493]
Pantethine Benefits
| Pantethine is a derivative of vitamin B5 and the stable disulfate form of pantetheine. Pantetheine is the active component of Coenzyme A (CoA). It has been reported that pantethine raises the levels of CoA, a cofactor involved in several metabolic pathways including carbohydrate and lipid metabolism. It also has been found that it may exert cholesterol-lowering effect on various population groups. |
THIS WEBSITE TALKS ABOUT THE SIDE EFFECTS AND THE POTENTIAL HEALTH BENEFITS OF HERBS, SUPPLEMENTS,
PHYTONUTRIENTS AND DRUG PRODUCTS. THIS WEBSITE ALSO TALKS ABOUT SOME POPULAR HEALTH ISSUES AND DISEASES.
ARTICLES IN THIS WEB SITE IS FOR YOUR REFERENCE ONLY. IF YOU HAVE ANY QUESTION, YOU SHOULD CONSULT WITH YOUR
DOCTOR IMMEDIATELY. ALL RIGHTS RESERVED 2008. DO NOT COPY NOR TRANSFER ARTICLES TO OTHER WEBSITES NOR OTHER
FORMS OF PUBLICATIONS. Privacy Policy. ARTICLE INDEX
PHYTONUTRIENTS AND DRUG PRODUCTS. THIS WEBSITE ALSO TALKS ABOUT SOME POPULAR HEALTH ISSUES AND DISEASES.
ARTICLES IN THIS WEB SITE IS FOR YOUR REFERENCE ONLY. IF YOU HAVE ANY QUESTION, YOU SHOULD CONSULT WITH YOUR
DOCTOR IMMEDIATELY. ALL RIGHTS RESERVED 2008. DO NOT COPY NOR TRANSFER ARTICLES TO OTHER WEBSITES NOR OTHER
FORMS OF PUBLICATIONS. Privacy Policy. ARTICLE INDEX
 | |  | |  | |  | |  | |  | |  |